Planning a phase I study of minor salivary gland derived autologous MSCs for prevention of long-term radiation induced xerostomia

计划对小唾液腺来源的自体 MSC 进行 I 期研究，以预防长期辐射引起的口干症

• 批准号: 10720234
• 负责人: RANDALL J KIMPLE
• 金额: $ 15万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10720234
• 关键词: Academic Medical Centers; Acupuncture Therapy; Acute; Adipose tissue; Affect; Allogenic; Amifostine; Autologous; Autologous Transplantation; Bone Marrow; Cancer Center; Candy; Caring; Cell Therapy; Cells; Characteristics; Chewing Gum; Cholinergic Agonists; Clinical; Clinical Protocols; Clinical Research; Clinical Trials; Conduct Clinical Trials; Cryopreservation; Data; Deglutition; Dental caries; Dentition; Development; Dimensions; Disease; Dysgeusia; Ensure; Environment; Esthesia; Fatigue; Functional disorder; Goals; Head and Neck Cancer; Head and neck structure; Hyperbaric Oxygen; Impairment; Infection; Information Systems; Infrastructure; Injections; Institution; Interferon Type II; Lead; Licensing; Lubricants; Manuals; Minor salivary gland structure; Mus; Nutritional status; Outcome; Patients; Pharmaceutical Preparations; Phase; Pilot Projects; Population; Preparation; Prevention; Preventive therapy; Preventive treatment; Primary Neoplasm; Procedures; Production; Public Health; Quality of life; Radiation; Radiation therapy; Recommendation; Recovery; Regenerative capacity; Reporting; Research Design; Research Personnel; Resources; Role; Safety; Saliva; Salivary; Salivary Glands; Site; Sleep; Social Functioning; Stimulant; Structure; System; Taste Perception; Technology; Therapeutic; Time; Tissues; Toxic effect; United States National Institutes of Health; Universities; Water; Wisconsin; Work; Xerostomia; clinical trial protocol; effective therapy; emotional functioning; experience; first-in-human; head and neck cancer patient; improved; innovation; lymph nodes; medical schools; mesenchymal stromal cell; morphogens; nutrition; phase 1 study; phase I trial; preclinical study; prevent; research clinical testing; safety testing; saliva composition; saliva function; side effect; stem cell biology; success; sucking; tool

Project Abstract Dry mouth is a significant side-effect of radiation therapy for head and neck cancer patients. Several factors contribute to dry mouth. Decreased production of saliva is called hyposalivation. Poor quality and function of saliva is called salivary dysfunction. Together, these cause xerostomia, or what a patient experiences as simply dry mouth. Xerostomia can lead to tooth decay, infections, difficulty speaking, impaired swallowing, poor nutrition, and has a significant negative effect on quality of life. Doctors recommend that patients suck on hard candy, chew gum, use saliva substitutes, and/or carry a water bottle with them at all times. None of these are particularly effective. Our long-term goal is to prevent the development of long-term radiation-induced dry mouth to improve the quality of life for patients with head and neck cancer. We seek to achieve this goal by providing convincing evidence that innovative cellular therapies can safely and significantly prevent the development of long-term salivary gland dysfunction. The team of investigators tackling this project is uniquely suited to complete the work. Success would lead directly to the next phase of clinical testing. We have expertise in caring for head and neck cancer patients, developing minor salivary gland derived mesenchymal stromal cells (MSCs) as cellular therapies, and studying salivary function. The overall objective of this application is to plan and prepare for a Phase 1 trial to test the safety and tolerability of IFN-g pre-licensed minor salivary gland derived MSCs for prevention of radiation-induced xerostomia in head and neck cancer patients. To achieve our goals, we propose a milestone-based project in which we will work closely with the NIH and FDA to finalize study design for a Phase 1 safety and tolerability study, complete the clinical trial protocol, and submit regulatory documents in Aim 1. In Aim 2, we will complete all necessary milestones to activate the proposed clinical trial including safety systems, data systems, and site staff and facility preparation to ensure a smooth opening to the planned clinical trial.

项目摘要 口干是头颈癌患者放射治疗的重要副作用。几个因素 有助于干嘴。唾液的产生减少称为造成损失。质量不佳和功能 唾液称为唾液功能障碍。这些同时引起静脉症，或者患者所经历的 只需干嘴。静态症可能导致蛀牙，感染，说话困难，吞咽障碍，差 营养，对生活质量产生重大负面影响。医生建议患者用力吮吸 糖果，咀嚼口香糖，使用唾液替代品和/或随时随身携带水瓶。这些都不是 特别有效。我们的长期目标是防止长期辐射引起的干燥的发展 口腔以改善头颈癌患者的生活质量。我们试图通过 提供令人信服的证据，表明创新的蜂窝疗法可以安全，显着防止 长期唾液腺功能障碍的发展。解决该项目的调查人员团队是唯一的 适合完成工作。成功将直接导致下一阶段的临床测试。我们有 在照顾头颈癌患者方面的专业知识，开发出较小的唾液腺衍生的间充质 基质细胞（MSC）作为细胞疗法，并研究唾液功能。总体目标 应用是计划和准备1阶段试验，以测试IFN-G预先许可的IFN-G的安全性和耐受性 小唾液腺衍生的MSC，用于预防辐射诱导的头颈癌中的静态症 患者。为了实现我们的目标，我们提出了一个基于里程碑的项目，我们将与该项目紧密合作 NIH和FDA要完成1阶段安全性和耐受性研究的研究设计，请完成临床试验 协议，并在AIM 1中提交监管文件。在AIM 2中，我们将完成所有必要的里程碑 激活拟议的临床试验，包括安全系统，数据系统以及现场人员和设施准备 确保对计划的临床试验进行平稳开放。